Clinical Context Key to Interpreting Autoimmune Serologies in Dermatology
Autoimmune serologies can inform diagnosis, risk assessment, and disease monitoring in dermatology, but results must be interpreted within the patient’s clinical context, according to Joseph F. Merola, MD, MMSc, FAAD, FACR, at the Masterclasses in Dermatology NP/PA Institute.
During his presentation, “Interpretation of Autoimmune Serologies for the Dermatology NP/PA,” Dr Merola reviewed antinuclear antibodies (ANA), lupus-specific antibodies, antiphospholipid antibodies, and systemic sclerosis-associated antibodies.
ANA positivity depends substantially on serum dilution and patient age. Among randomly selected healthy individuals, 30% had a positive ANA at a 1:40 dilution, compared with 13% at 1:80, 5% at 1:160, and 3% at 1:320. A 1:160 dilution “probably yields the optimal balance between sensitivity and specificity in most labs,” according to Dr Merola. However, he emphasized that ANA interpretation “is all about clinical context.”
Serologic monitoring also has implications for systemic lupus erythematosus (SLE). In a study of 500 patients with mild or inactive SLE, 1 in 4 developed a clinically silent laboratory abnormality over 2 years that could prompt a management change. Monitoring every 3 to 6 months was recommended depending on underlying disease activity.
Specific antibodies can provide additional clinical information. Anti-dsDNA is associated with glomerulonephritis and more severe SLE and can track with disease activity. Anti-Ro antibodies are associated with subacute cutaneous lupus erythematosus, photosensitivity, neonatal lupus, cutaneous vasculitis, and Sjögren syndrome.
For antiphospholipid antibody evaluation, testing should include lupus anticoagulant, anticardiolipin IgG/IgM, and anti-β2 glycoprotein-1 IgG/IgM.
Dr Merola wrapped up his presentation by sharing how pregnancy represents another important setting for serologic interpretation. In anti-SSA/Ro-positive pregnancies, hydroxychloroquine should be considered, with the presentation citing a 77% to 86% relative risk reduction in fetal congenital heart block.
Reference
Merola J. Interpretation of autoimmune serologies for the dermatology NP/PA. Presented at: Masterclasses in Dermatology NP/PA Institute; October 17–18, 2026; Dallas, TX.
© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of the Dermatology Learning Network or HMP Global, their employees, and affiliates.
Related Content
Where Dermatology NPs and PAs Learn, Lead, and Level Up.
The Derm NP/PA is dedicated to educating and informing advanced practice providers on clinical topics and practical issues to support the profession and improve the quality of patient care across the spectrum of dermatology.
The Derm NP/PA is designed for advanced practice providers who specialize in dermatology to further their education and increase their knowledge to achieve better patient outcomes. Explore cutting-edge research, innovative treatment options, and new therapeutic methods while remaining focused on the fundamental principles and terminology associated with dermatology. Engage year-round with The Derm NP/PA to access clinical insights, interactive features, research news updates, accredited continuing-education programs, and more.
